Home > Insider Trading > Filing (0000078003-11-000014)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
902622	Icagen Inc	ICGN	Pharmaceutical Preparations (2834)	561785001

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
78003	Pfizer Inc	235 E 42Nd St New York NY 10017		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-09-02	4,611,921	$6.00	4,611,921	No	4	P	Indirect	by Eclipse Acquisition Corp.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	by Eclipse Acquisition Corp.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,067,015	Direct

Footnotes

This filing is being amended to adjust the number of shares of Common Stock (hereinafter defined) acquired as reported in Table I, Box 4 and the number of shares of Common Stock beneficially owned as reported in Table I, Box 5 which were previously reported as 4,617,045. The adjusted amount for each of Box 4 and Box 5 of Table I is 4,611,921.
This adjustment results from the failure of certain shareholders to deliver 5,124 shares of Common Stock tendered pursuant to notices of guaranteed delivery, as executed in conjunction with a tender offer by Eclipse Acquisition Corp. ("Purchaser"), a wholly-owned subsidiary of Pfizer Inc. ("Parent"), for all of the issued and outstanding common stock, $0.001 par value per share (the "Common Stock") of Icagen, Inc.
Includes 1,067,015 shares previously directly owned by Parent.